Health

Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.

Shotlee·December 12, 2025·Updated Jan 27, 2026·1 min read

Novo Nordisk Introduces Ozempic in India

Novo Nordisk has officially launched Ozempic (injectable semaglutide) in India. This marks the availability of a widely used once-weekly GLP-1 receptor agonist for adults dealing with uncontrolled type 2 diabetes. The company stated that Ozempic® is designed to supplement diet and exercise, arriving at a crucial time for India, which is experiencing a surge in diabetes cases.

According to WHO's 2023-24 estimates, India has 101 million individuals living with diabetes. An additional 136 million are classified as prediabetic, and 254 million are affected by generalized obesity. These figures underscore the pressing need for effective treatment solutions. Health tracking apps like Shotlee can help monitor blood sugar levels and medication adherence.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Become aBeta Tester

Novo Nordisk India MD Vikrant Shrotriya pointed out that many patients face the dual challenge of diabetes and excess weight, making Ozempic a suitable therapeutic option. He also noted that the company is aware of India's socioeconomic realities. To improve accessibility, the medication has been priced at Rs 2,200 per week.

Original source: The Times of India

View original article →

#Ozempic#diabetes India#Novo Nordisk#type 2 diabetes#semaglutide#GLP-1#obesity#India

Metabolic Health

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.

GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk Introduces Ozempic in India

📱 Get the Shotlee App

Related Articles

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk Introduces Ozempic in India

📱 Get the Shotlee App

Related Articles

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds